Nebenwirkungen · Nulojix
NULOJIX 250 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11
HOS-213627 · Präparat HOS-155150
Malignancies and post-transplant lymphoproliferative disease In the newly transplanted patient trials, Year 1 and 3 frequencies of malignancies are shown in Table 3, except for cases of PTLD which are presented at 1 year and > 3 years (median days of follow- up were 1,199 days for belatacept MI, 1,206 days for belatacept LI, and 1,139 days for ciclosporin). The Year 3 frequency of malignant neoplasms, excluding non-melanoma skin cancers, was similar in the belatacept LI and ciclosporin groups and higher in the belatacept MI group. PTLD occurred at a higher rate in both belatacept treatment groups versus ciclosporin (see section 4.4). Non-melanoma skin cancers occurred less frequently with the belatacept LI regimen than with the ciclosporin or belatacept MI regimens.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-20T13:32:00Z · SHA-256 699ad0365be092c03037bcab8ddbe9297f4376d0afffb7e9c952313b11ba0943 · Passage 968dee7410544be1c570519a52357bed989f43a767793c702a40f3323ca61094 · Zeichen 10748–11524 im Abschnitt